Cardior Pharmaceuticals GmbH has closed a €64m series B financing round that will help the German biotech take its non-coding RNA candidate into mid-stage trials for heart failure.
Cardior Counts On RNA To Tackle Cardiac Disease
Raises €64m In Series B Financing
The German firm intends to use the proceeds from an over-subscribed round to move its micro-RNA-132 inhibitor forward into trials for heart failure and advance its pipeline.
More from Cardiovascular
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
The UK giant is forecasting peak sales of $5bn plus
More from Therapy Areas
• By
The ZENITH study is a landmark for Merck’s first-in-class activin signalling inhibitor and pulmonary arterial hypertension treatment.
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.